Purinosin Syrup (Inosiphylex)

Adult dose

(Tablets) 1. Adults: Administer inosiplex 3～4 g per day orally in divided doses of 500 mg～1 g every 4～6 hours. (Syrup) 1. Adults Administer inosiplex 3～4 g per day (60～80 mL of this drug) orally in divided doses of 500 mg～1g (10～20 mL) every 4～6 hours.

Child dose

(Tablets) 2. Children: Administer 50～100 mg per kg of body weight per day orally in 6 divided doses. (Syrup) 2. Children: Administer 50～100 mg per kg of body weight per day orally in 6 divided doses.

This medication should not be used in patients who have shown an allergic reaction to this medication or its ingredients. It should be used cautiously in patients with gout or hyperuricemia, or those with a history of these conditions, as it may increase blood uric acid levels and worsen symptoms. Patients with urinary stones or kidney stones should also use this medication with caution since it may elevate blood and urine uric acid levels, exacerbating symptoms. In patients with impaired kidney function, uric acid excretion may be delayed, necessitating caution. Patients taking the heart medication digoxin should be aware that this medication may affect the heart. Taking this medication may cause gastrointestinal discomfort, including upper abdominal discomfort, diarrhea, constipation, nausea, vomiting, and abdominal pain. Rarely, gastrointestinal bleeding may occur. Possible blood-related issues include increased red blood cell count, decreased white blood cell count, and increased platelet count. Liver function test results may rise, so liver health should be monitored closely. Allergic reactions such as skin rashes may occur. This medication may elevate blood uric acid levels, leading to hyperuricemia. It may affect the kidneys and urinary system, leading to elevated BUN levels, kidney stones accompanied by hypercalcemia, frequent urination, and urinary stones. Neurological symptoms such as headache, dizziness, fatigue, lethargy, irritability, drowsiness, and insomnia may be experienced. Arthralgia may develop, and rarely, respiratory diseases such as interstitial pneumonia may occur, so caution is advised. Given this medication's potential to raise uric acid levels in blood and urine, regular monitoring of uric acid levels and kidney function tests is recommended during treatment. It is advised to avoid concurrent use of medications such as cortisone, globulin, immunosuppressants, and anti-lymphocyte globulin with this medication. The safety of this medication during pregnancy is not well established, so women who are pregnant or may become pregnant should carefully weigh the benefits and risks of using this medication. Especially, it is advisable not to use it during the first three months of pregnancy. In breastfeeding mothers, as this medication may be transmitted through breast milk, it is advisable to refrain from breastfeeding during the administration period. In rare cases, overdose may result in vomiting, headache, upper abdominal discomfort, dizziness, and palpitations, but these symptoms will subside with reduction or cessation of the dosage. Treatment and supportive therapy should be administered based on symptoms in case of overdose.

Upper abdominal discomfort, diarrhea, constipation, gastrointestinal bleeding, nausea, vomiting, stomachache, increased red blood cells, decreased white blood cells, increased platelets, elevated AST/ALT, elevated γ-GTP, elevated ALP, elevated LDH, rash, hyperuricemia, increased BUN, kidney stones accompanied by hypercalcemia, polyuria, urinary stones, headache, dizziness, fatigue, lethargy, irritability, drowsiness, insomnia, arthralgia, interstitial pneumonia, palpitations

This medication should be stored in a tightly sealed container to prevent air and moisture from entering, preferably at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain the medication's efficacy and prevent deterioration.

Appearance

A syrup with a reddish to purple color and a distinctive scent.

Package unit

100mL/bottle, 500mL/bottle